Drug Trial Radar · NCT07799129
Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Eddingpharm (Zhuhai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This Phase 2 clinical study comprises two phases: a randomized, double-blind, placebo parallel-controlled core study and an open-label extension study.
Conditions
- Mixed Dyslipidemia
Interventions
EDP167 100mgDrug
EDP167 100 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 100 mg once every 3 months in the extension study.
EDP167 200mgDrug
EDP167 200 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 200 mg once every 3 months in the extension study.
EDP167 300mgDrug
EDP167 300 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 300 mg once every 3 months in the extension study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change from Baseline in Serum Triglycerides (TG) Levels at Week 24Time frame: From baseline to week 24 of the core study
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.